Yarrow Bioscience (YARW) Assets Average (2018 - 2026)
Yarrow Bioscience's (YARW) quarterly Assets Average came in at $28.0 million in Q1 2026, down 54.57% YoY from $61.7 million in Q1 2025, and down 25.17% on a QoQ basis from $37.4 million in Q4 2025.
Yarrow Bioscience (YARW) Assets Average (2018 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 9 years of Assets Average data on file, last reported at $28.0 million in Q1 2026.
- Quarterly Assets Average fell 54.57% year-over-year to $28.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.0 million (down 54.57% YoY) and the FY2025 annual result came in at $48.5 million, down 41.03% from the prior year.
- Assets Average slipped to $28.0 million in Q1 2026, from $37.4 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $94.7 million in Q1 2024 to a low of $22.1 million in Q3 2023.
- A 5-year average of $55.2 million and a median of $54.8 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average sank 57.79% — and 2024, when it jumped 268.21%.
- Tracing YARW's Assets Average over 5 years: stood at $43.8 million in 2022, then jumped by 33.41% to $58.5 million in 2023, then gained by 22.36% to $71.6 million in 2024, then slumped by 47.68% to $37.4 million in 2025, then slipped by 25.17% to $28.0 million in 2026.
- The last three Assets Average figures came in at $28.0 million (Q1 2026), $37.4 million (Q4 2025), and $50.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 19.82 Bn |
| 10 | Yarrow Bioscience | 30.79 Mn | 7.86 Mn | - | 24.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.74 Mn |
| Mar 31, 2026 | 28.02 Mn |
| Dec 31, 2025 | 37.44 Mn |
| Jun 30, 2025 | 50.57 Mn |
| Mar 31, 2025 | 61.66 Mn |
| Dec 31, 2024 | 71.55 Mn |
| Sep 30, 2024 | 81.42 Mn |
| Jun 30, 2024 | 89.16 Mn |
| Mar 31, 2024 | 94.68 Mn |
| Dec 31, 2023 | 58.48 Mn |
| Sep 30, 2023 | 22.11 Mn |
| Jun 30, 2023 | 30.11 Mn |
| Mar 31, 2023 | 38.01 Mn |
| Dec 31, 2022 | 43.83 Mn |
| Sep 30, 2022 | 51.05 Mn |
| Jun 30, 2022 | 59.76 Mn |
| Mar 31, 2022 | 65.68 Mn |
| Dec 31, 2021 | 74.18 Mn |
| Sep 30, 2021 | 107.65 Mn |
| Jun 30, 2021 | 141.58 Mn |